On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsAudio – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Developing Personalized Immunotherapies for Advanced Breast Cancer Treatment

Company: BriaCell Therapeutics Corp. (BCTXF)
Category: News

Related Editorial
Personalized treatment for advanced breast cancer is a massive global medical need. According to latest figures from the Centers for Disease Control, in the United States alone more than 41,000 women die from breast cancer each year. Hope is on the horizon, however, as innovative biomedical companies apply their research and technologies to bring personalized immunotherapies to market for this unmet medical need. Among these companies is BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) (BCTXF Profile), an immune-oncology-focused biotech company developing the first off-the-shelf personalized immunotherapy for advanced breast cancer. The company’s technology is based on a targeted immunotherapy regime that has seen encouraging results in clinical trials. Other biotechs in the personalized cancer immunotherapy space include Gilead Sciences, Inc. (NASDAQ: GILD), the parent company of Kite Pharma; Cellectis S.A. (NASDAQ: CLLS); Neon Therapeutics, Inc. (NASDAQ: NTGN); and Loxo Oncology, Inc. (NASDAQ: LOXO).

To view the full editorial, visit http://nnw.fm/pJK3t

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination study with pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense, and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217